In addition, the consistent findings among the various kidney-specific and cardiorenal composite end points in this analysis and compared with results with SGLT2 inhibitors in other CKD studies support a class effect on kidney outcomes. This evidence concerns the gene SLC5A2 and chronic kidney disease.